CannTrust Ships CBD Oil Capsules to Gold Coast University for Clinical Trial on Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND)

VAUGHAN, ON, Nov. 26, 2018 /PRNewswire/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”) (TSX: TRST), one of Canada’s leading and most trusted licensed producers of cannabis, announced today that it has shipped its standardized CBD oil capsules to Australia’s Gold Coast University Hospital. The capsules will be used in a study to determine the efficacy of CannTrust CBD oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND), which was first announced by the Company in July 2018. The capsules will be imported, stored and distributed by PharmaCann Pty Ltd (“PharmaCann”). The shipment will include all investigational products that are required for the study.

This study exemplifies CannTrust’s focus on medical research and its dedication to uncovering the medicinal value of its proprietary cannabis products, and how they can improve health and well-being

... read more at: https://www.prnewswire.com/news-releases/canntrust-ships-cbd-oil-capsules-to-gold-coast-university-for-clinical-trial-on-amyotrophic-lateral-sclerosis-als-and-motor-neuron-disease-mnd-300754877.html

by

Leave a Reply